Actuate Therapeutics Inc.
ACTU
Class-Leading GSK-3 Inhibitor We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 ( GSK-3 ). We are developing elraglusib, an ATP-competitive small molecule that is designed to enter cancer cells and block the function of the enzyme glycogen sy…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$18M
▲ +18.5% YoY
Op. Margin
–
ROIC
-466.38%
▲ +37714.0pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$16M
▲ +12.1% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$2M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with ACTU
Actuate Therapeutics (ACTU) in two numbers
Questions about Actuate Therapeutics
Does Actuate Therapeutics (ACTU) pay a dividend?
No. Actuate Therapeutics (ACTU) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 13 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in ACTU's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ACTU
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.